Mid-to-long term mortality following surgical versus percutaneous coronary revascularization stratified according to stent subtype: An analysis of 6,682 patients with multivessel disease

Shahzad G Raja, Charles Ilsley, Fabio De Robertis, Rebecca Lane, Tito Kabir, Toufan Bahrami, Andre Simon, Aron Popov, Miles C Dalby, Mark Mason, Richard Grocott-Mason, Robert D Smith, M Bilal Iqbal, Shahzad G Raja, Charles Ilsley, Fabio De Robertis, Rebecca Lane, Tito Kabir, Toufan Bahrami, Andre Simon, Aron Popov, Miles C Dalby, Mark Mason, Richard Grocott-Mason, Robert D Smith, M Bilal Iqbal

Abstract

Background: Studies comparing coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) have largely been performed in the bare-metal stent (BMS) and first-generation drug eluting stent (F-DES) era. Second-generation DES (S-DES) have shown improved outcomes when compared to F-DES, but data comparing CABG with PCI using S-DES is limited. We compared mortality following CABG versus PCI for patients with multivessel disease and analyzed different stent types.

Methods: A total of 6,682 patients underwent multivessel revascularization at Harefield Hospital, UK. We stratified CABG patients into single arterial graft (SAG) or multiple arterial grafts (MAG); and PCI patients into BMS, F-DES or S-DES groups. We analyzed all-cause mortality at 5 years.

Results: 4,388 patients had CABG (n[SAG] = 3,358; n[MAG] = 1,030) and 2,294 patients had PCI (n[BMS] = 416; n[F-DES] = 752; n[S-DES] = 1,126). PCI had higher 5-year mortality with BMS (HR = 2.27, 95% CI:1.70-3.05, p<0.001); F-DES (HR = 1.52, 95% CI:1.14-2.01, p = 0.003); and S-DES (HR = 1.84, 95% CI:1.42-2.38, p<0.001). This was confirmed in inverse probability treatment weighted analyses. When adjusting for both measured and unmeasured factors using instrumental variable analyses, PCI had higher 5-year mortality with BMS (Δ = 15.5, 95% CI:3.6,27.5, p = 0.011) and FDES (Δ = 16.5, 95% CI:6.6,26.4, p<0.001), but had comparable mortality with CABG for PCI with SDES (Δ = 0.9, 95% CI: -9.6,7.9, p = 0.844), and when exclusively compared to CABG patients with SAG (Δ = 0.4, 95% CI: -8.0,8.7, p = 0.931) or MAG (Δ = 4.6, 95% CI: -0.4,9.6, p = 0.931).

Conclusions: In this real-world analysis, when adjusting for measured and unmeasured confounding, PCI with SDES had comparable 5-year mortality when compared to CABG. This warrants evaluation in adequately-powered randomized controlled trials.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629–38. Epub 2013/02/27. doi: .
    1. Hannan EL, Racz MJ, McCallister BD, Ryan TJ, Arani DT, Isom OW, et al. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Journal of the American College of Cardiology. 1999;33(1):63–72. Epub 1999/02/06. .
    1. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. The New England journal of medicine. 2005;352(21):2174–83. Epub 2005/05/27. doi: .
    1. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. The New England journal of medicine. 2008;358(4):331–41. Epub 2008/01/25. doi: .
    1. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123(13):1400–9. Epub 2011/03/23. doi: .
    1. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125(23):2873–91. Epub 2012/05/16. doi: .
    1. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ (Clinical research ed). 2012;345:e5170 Epub 2012/08/14. doi: .
    1. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology (Cambridge, Mass). 2000;11(5):550–60. Epub 2000/08/24. .
    1. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA: the journal of the American Medical Association. 1994;272(11):859–66. Epub 1994/09/21. .
    1. Venkitachalam L, Lei Y, Magnuson EA, Chan PS, Stolker JM, Kennedy KF, et al. Survival benefit with drug-eluting stents in observational studies: fact or artifact? Circulation Cardiovascular quality and outcomes. 2011;4(6):587–94. Epub 2011/10/13. .
    1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European heart journal. 2014;35(37):2541–619. Epub 2014/09/01. doi: .
    1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Journal of the American College of Cardiology. 2011;58(24):e44–122. Epub 2011/11/11. doi: .
    1. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. The New England journal of medicine. 2004;350(3):221–31. Epub 2004/01/16. doi: .
    1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. The New England journal of medicine. 2003;349(14):1315–23. Epub 2003/10/03. doi: .
    1. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364(9434):583–91. Epub 2004/08/18. doi: .
    1. Dirksen MT, Vink MA, Suttorp MJ, Tijssen JG, Patterson MS, Slagboom T, et al. Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2008;4(1):64–70. Epub 2008/12/31. .
    1. Kaltoft A, Kelbaek H, Thuesen L, Lassen JF, Clemmensen P, Klovgaard L, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. Journal of the American College of Cardiology. 2010;56(8):641–5. Epub 2010/08/07. doi: .
    1. Piscione F, Piccolo R, Cassese S, Galasso G, De Rosa R, D'Andrea C, et al. Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2010;5(7):853–60. Epub 2010/02/10. .
    1. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. The New England journal of medicine. 2015;372(13):1213–22. Epub 2015/03/17. doi: .
    1. Lytle BW, Blackstone EH, Sabik JF, Houghtaling P, Loop FD, Cosgrove DM. The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. The Annals of thoracic surgery. 2004;78(6):2005–12; discussion 12–4. Epub 2004/11/25. doi: .
    1. Zacharias A, Habib RH, Schwann TA, Riordan CJ, Durham SJ, Shah A. Improved survival with radial artery versus vein conduits in coronary bypass surgery with left internal thoracic artery to left anterior descending artery grafting. Circulation. 2004;109(12):1489–96. Epub 2004/03/17. doi: .
    1. Kurlansky PA, Traad EA, Dorman MJ, Galbut DL, Zucker M, Ebra G. Thirty-year follow-up defines survival benefit for second internal mammary artery in propensity-matched groups. The Annals of thoracic surgery. 2010;90(1):101–8. Epub 2010/07/09. doi: .
    1. Puskas JD, Sadiq A, Vassiliades TA, Kilgo PD, Lattouf OM. Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients. The Annals of thoracic surgery. 2012;94(3):710–5; discussion 5–6. Epub 2012/06/09. doi: .
    1. Schwann TA, Engoren M, Bonnell M, Clancy C, Habib RH. Comparison of late coronary artery bypass graft survival effects of radial artery versus saphenous vein grafting in male and female patients. The Annals of thoracic surgery. 2012;94(5):1485–91. Epub 2012/07/10. doi: .
    1. Buxton BF, Shi WY, Tatoulis J, Fuller JA, Rosalion A, Hayward PA. Total arterial revascularization with internal thoracic and radial artery grafts in triple-vessel coronary artery disease is associated with improved survival. The Journal of thoracic and cardiovascular surgery. 2014;148(4):1238–43; discussion 43–4. Epub 2014/08/19. doi: .
    1. Taggart DP, Altman DG, Gray AM, Lees B, Nugara F, Yu LM, et al. Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). European heart journal. 2010;31(20):2470–81. Epub 2010/09/02. doi: .
    1. Habib RH, Dimitrova KR, Badour SA, Yammine MB, El-Hage-Sleiman AK, Hoffman DM, et al. CABG Versus PCI: Greater Benefit in Long-Term Outcomes With Multiple Arterial Bypass Grafting. Journal of the American College of Cardiology. 2015;66(13):1417–27. Epub 2015/09/26. doi: .
    1. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA: the journal of the American Medical Association. 2007;297(18):2001–9. Epub 2007/05/10. doi: .
    1. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA: the journal of the American Medical Association. 2007;297(3):278–85. Epub 2007/01/18. doi: .
    1. Yeh RW, Vasaiwala S, Forman DE, Silbaugh TS, Zelevinski K, Lovett A, et al. Instrumental variable analysis to compare effectiveness of stents in the extremely elderly. Circulation Cardiovascular quality and outcomes. 2014;7(1):118–24. Epub 2013/11/21. doi: .
    1. Park S-J, Ahn J-M, Kim Y-H, Park D-W, Yun S-C, Lee J-Y, et al. Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease. New England Journal of Medicine. 2015;372(13):1204–12. doi: .
    1. A Trial to Evaluate a New Strategy in the Functional Assessment of 3-vessel Disease Using the SYNTAX II Score in Patients Treated With PCI. ClinicalTrialsgov ().
    1. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51. Epub 2007/05/02. doi: .

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe